JPS58126866A - （フエニル−４ピペラジニルエチル）−２アニリンより誘導された新規のイミン、その製法及び治療剤としての使用 - Google Patents
（フエニル−４ピペラジニルエチル）−２アニリンより誘導された新規のイミン、その製法及び治療剤としての使用Info
- Publication number
- JPS58126866A JPS58126866A JP57192339A JP19233982A JPS58126866A JP S58126866 A JPS58126866 A JP S58126866A JP 57192339 A JP57192339 A JP 57192339A JP 19233982 A JP19233982 A JP 19233982A JP S58126866 A JPS58126866 A JP S58126866A
- Authority
- JP
- Japan
- Prior art keywords
- product according
- chain
- phenyl
- active ingredient
- chenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 9
- 150000002466 imines Chemical class 0.000 title description 5
- 238000004519 manufacturing process Methods 0.000 title description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 229910052736 halogen Chemical group 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 230000000506 psychotropic effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 4
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000008018 melting Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 229960004046 apomorphine Drugs 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 230000002804 anti-anaphylactic effect Effects 0.000 description 2
- 230000001705 anti-serotonergic effect Effects 0.000 description 2
- 230000000794 anti-serotonin Effects 0.000 description 2
- 239000003420 antiserotonin agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010017543 Fungal skin infection Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003326 anti-histaminergic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000010248 power generation Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8120563 | 1981-11-03 | ||
| FR8120563A FR2515647A1 (fr) | 1981-11-03 | 1981-11-03 | Nouvelles imines derivees de (phenyl-4 piperazinylethyl)-2 anilines, leur methode de preparation et leur application therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS58126866A true JPS58126866A (ja) | 1983-07-28 |
Family
ID=9263639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57192339A Pending JPS58126866A (ja) | 1981-11-03 | 1982-11-01 | （フエニル−４ピペラジニルエチル）−２アニリンより誘導された新規のイミン、その製法及び治療剤としての使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0078757B1 (enExample) |
| JP (1) | JPS58126866A (enExample) |
| CA (1) | CA1199917A (enExample) |
| DE (1) | DE3266055D1 (enExample) |
| ES (1) | ES517095A0 (enExample) |
| FR (1) | FR2515647A1 (enExample) |
| MA (1) | MA19632A1 (enExample) |
| OA (1) | OA07243A (enExample) |
| PT (1) | PT75776B (enExample) |
| ZA (1) | ZA828043B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06179670A (ja) * | 1992-06-12 | 1994-06-28 | Adir | 新規１，４−二置換ピペラジン類それらの製造法および医薬品組成物 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2559481B1 (fr) * | 1984-02-10 | 1988-01-08 | Rhone Poulenc Agrochimie | Nouveaux derives de phenyliminomethyl-3 pyridine, leur preparation et leur utilisation pour la preparation de derives de pyridylacetonitriles utilisables comme antifongiques |
| FR2632641B1 (fr) * | 1988-06-13 | 1990-10-12 | Irceba | ((aryl-4-piperazinyl-1)-2 ethoxy)-3 p-cymene, les derives ortho, meta, para monosubstitues ou disubstitues sur le noyau phenyle dudit produit, le procede de preparation desdits derives, et les medicaments contenant lesdits composes comme principe actif |
| GB2499991A (en) | 2012-03-05 | 2013-09-11 | Solaredge Technologies Ltd | DC link circuit for photovoltaic array |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2476644A1 (fr) * | 1980-02-21 | 1981-08-28 | Sarget Lab | Orthoarylydeneaminophenethylamine, leur preparation et leur utilisation therapeutique |
-
1981
- 1981-11-03 FR FR8120563A patent/FR2515647A1/fr active Granted
-
1982
- 1982-10-27 EP EP82450015A patent/EP0078757B1/fr not_active Expired
- 1982-10-27 DE DE8282450015T patent/DE3266055D1/de not_active Expired
- 1982-11-01 JP JP57192339A patent/JPS58126866A/ja active Pending
- 1982-11-01 MA MA19844A patent/MA19632A1/fr unknown
- 1982-11-02 CA CA000414678A patent/CA1199917A/fr not_active Expired
- 1982-11-02 PT PT75776A patent/PT75776B/pt not_active IP Right Cessation
- 1982-11-03 OA OA57836A patent/OA07243A/xx unknown
- 1982-11-03 ZA ZA828043A patent/ZA828043B/xx unknown
- 1982-11-03 ES ES517095A patent/ES517095A0/es active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06179670A (ja) * | 1992-06-12 | 1994-06-28 | Adir | 新規１，４−二置換ピペラジン類それらの製造法および医薬品組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0078757A1 (fr) | 1983-05-11 |
| ES8401051A1 (es) | 1983-12-01 |
| CA1199917A (fr) | 1986-01-28 |
| PT75776B (en) | 1985-07-26 |
| DE3266055D1 (en) | 1985-10-10 |
| MA19632A1 (fr) | 1983-07-01 |
| ZA828043B (en) | 1983-08-31 |
| ES517095A0 (es) | 1983-12-01 |
| FR2515647A1 (fr) | 1983-05-06 |
| FR2515647B1 (enExample) | 1984-08-24 |
| PT75776A (en) | 1982-12-01 |
| OA07243A (fr) | 1984-04-30 |
| EP0078757B1 (fr) | 1985-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07501330A (ja) | 新規な置換されたサリチル酸 | |
| JPS62230722A (ja) | 肥満および／または関連状態の治療剤 | |
| IT8348746A1 (it) | Derivati amminometil-benzenici arili-sostituiti ad attività regolatrice del ritmo cardiaco e composizioni che li contengono | |
| JPS5869812A (ja) | 血糖降下剤 | |
| US3058980A (en) | Substitution products of benzo- | |
| US2073100A (en) | Nu-aminoalkylamides of nu-alkyl-aminobenzoic acids and process of preparing them | |
| JPS58126866A (ja) | （フエニル−４ピペラジニルエチル）−２アニリンより誘導された新規のイミン、その製法及び治療剤としての使用 | |
| CN102438612A (zh) | 腈衍生物及其药学用途与组合物 | |
| US3953604A (en) | 1-(2-Substituted-chromonyloxy)-2-hydroxy-3-(substituted phenoxy)propanes | |
| JPS59205339A (ja) | ロイコトリエン「きっ」抗物質 | |
| JP2959598B2 (ja) | 光学活性なチエノトリアゾロジアゼピン化合物 | |
| JPH0153266B2 (enExample) | ||
| US3920839A (en) | Adamantylcarboxamidophenylalkanoic acids and esters thereof for treating inflammatory disorders and allergies | |
| JPS59199679A (ja) | 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物 | |
| AU665968B2 (en) | New non ionic iodized agents for X-ray contrasting, method for preparing them and galenical compositions containing them | |
| US2419230A (en) | Therapeutic compositions and method of preparing same | |
| US1969828A (en) | Sedative compounds | |
| US3056792A (en) | Unsymmetrical 1, 3-diamino-2-propanols | |
| US3862320A (en) | Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide | |
| JPS6042367A (ja) | 抗腫瘍剤としてのフエニルキノリンカルボン酸および誘導体 | |
| US4122202A (en) | Amino-3H-isobenzofuranones N-substitutes and their therapeutic application | |
| US3109022A (en) | Nu-aryl anthranilic acids | |
| JPS60233092A (ja) | 環付加４ｈ‐１，４‐ベンゾチアジン誘導体 | |
| JPS6124593A (ja) | ピリミドイソキノリン誘導体 | |
| JPS5896045A (ja) | 新規なジフエニルアルカノアミン誘導体およびその製造法 |